Menopause and sarcopenia: A potential role for sex hormones.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts and existing literature without systematic methodology
PubMed 21353405 · doi:10.1016/j.maturitas.2011.01.014
What was done
This narrative review examined the role of sex hormone status (specifically estrogen decline during menopause) in the development of sarcopenia. It reviewed the physical and metabolic consequences of sarcopenia in postmenopausal women and discussed prevention and treatment strategies, including resistance exercise and hormonal supplementation.
What was found
The abstract reports no quantitative data or effect sizes. It notes that estrogen decline during menopause is associated with reduced muscle mass, decreased muscle strength, lower bone density, and increased visceral adiposity. Resistance training is reported to be effective in attenuating age-related muscle and strength loss, whereas clinical evidence regarding the efficacy of hormone supplementation remains contradictory.
Why it matters
It highlights the clinical importance of preserving muscle mass in postmenopausal women to avoid disability, reinforcing resistance exercise as an established intervention while clarifying that hormone therapy's role remains unresolved.
Limits
The abstract describes a narrative review rather than a systematic review or meta-analysis, provides no quantitative data, and includes no primary patient data. Findings on hormone supplementation remain contradictory and unresolved within the review.
Cited by
- supports Menopause accelerates muscle loss, leading to sarcopenia and anabolic resistance.